Facet Cuts Shareholder Deals To Fight Off Hostile Biogen Bid
Biogen Idec will drop its $450 million tender offer, but the companies still must work together to develop two key drugs.
Biogen Idec will drop its $450 million tender offer, but the companies still must work together to develop two key drugs.